Ovid Therapeutics Inc. reported cash, cash equivalents and marketable securities of $25.6 million as of September 30, 2025. This was supplemented by an $81 million private placement in October 2025, with up to an additional $94 million possible from warrants. Revenue from royalty agreements for the third quarter was $0.1 million, compared to $0.2 million in the same period in 2024. Research and development expenses decreased to $5.9 million from $7.9 million, while general and administrative expenses increased to $6.8 million from $5.5 million. Total operating expenses were $12.7 million, down from $13.4 million a year earlier. The net loss for the quarter was $12.2 million, or $0.17 per share, compared to a net loss of $14.0 million, or $0.20 per share, in 2024. Key business developments include the appointment of Meg Alexander as CEO effective January 1, 2026, and advancement of OV329, a next-generation GABA-aminotransferase inhibitor, which showed strong Phase 1 results and will proceed to Phase 2 studies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001636651-25-000011), on November 12, 2025, and is solely responsible for the information contained therein.
Comments